Paul Tudor Jones Tyme Technologies, Inc. Call Options Transaction History
Tudor Investment Corp Et Al
- $19.2 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
About TYME TECHNOLOGIES, INC.
- Ticker TYME
- Exchange NASDAQ
- Shares Outstandng 172,207,008
- Description
- Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...